Prostatype – White Paper

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

whitePaper | December 13, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period (2017-2022) encompasses a unique timeframe including the global COVID-19 pandemic.

whitePaper | September 29, 2022

The market is experiencing a surge in the availability of cell and gene therapies (CGTs); it’s estimated that by 2025 as many as 20 will be introduced into the US each year.1,2

whitePaper | November 17, 2022

Gene therapy is the modification of specific genes in targeted cells in order to address genetic mutations that cause some of the most debilitating human conditions.

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section